Literature DB >> 11782893

Interferon-gamma therapy: evaluation of routes of administration and delivery systems.

Husam M Younes1, Brian G Amsden.   

Abstract

Although different routes and delivery systems have been used to deliver interferon-gamma (IFN-gamma) for the treatment of a variety of viral and neoplastic diseases, little has been reported regarding the most efficient and least toxic routes and drug delivery modes required to achieve these goals. To have a greater understanding of the best strategies to use to administer this cytokine in an efficient, stable, and safe manner, this review details aspects of IFN-gamma concerning its mechanism of action, physical properties, and pharmacokinetics. One important conclusion that is drawn from this analysis is that a consistent, local concentration of IFN-gamma is necessary to achieve an optimal therapeutic response. A critical discussion covering the advantages and limitations of the currently used methodologies to deliver IFN-gamma in such a fashion is presented. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782893     DOI: 10.1002/jps.10007

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus.

Authors:  S Segura; C Gamazo; J M Irache; S Espuelas
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.

Authors:  Roshan J Thapa; Peirong Chen; Mitchell Cheung; Shoko Nogusa; Jianming Pei; Suraj Peri; Joseph R Testa; Siddharth Balachandran
Journal:  Mol Cancer Ther       Date:  2013-05-08       Impact factor: 6.261

3.  Interferon-γ causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis.

Authors:  Pippa F Cosper; Pamela A Harvey; Leslie A Leinwand
Journal:  Am J Pathol       Date:  2012-10-08       Impact factor: 4.307

Review 4.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

5.  Oxymatrine Sensitizes the HaCaT Cells to the IFN-γ Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.

Authors:  Chun-Jie Gao; Pei-Jun Ding; Li-Li Yang; Xu-Feng He; Meng-Jiao Chen; Dong-Ming Wang; Yan-Xin Tian; Hui-Min Zhang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

6.  Synthesis and characterization of polymer nanocarriers for the targeted delivery of therapeutic enzymes.

Authors:  Eric Simone; Thomas Dziubla; Vladimir Shuvaev; Vladimir R Muzykantov
Journal:  Methods Mol Biol       Date:  2010

Review 7.  Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.

Authors:  Siddharth Balachandran; Gregory P Adams
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

8.  Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector.

Authors:  Jiangxue Wu; Xia Xiao; Hongyun Jia; Jiemin Chen; Yinghui Zhu; Peng Zhao; Huanxin Lin; Wenlin Huang
Journal:  BMC Cancer       Date:  2009-02-16       Impact factor: 4.430

9.  Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo.

Authors:  Ling Zhang; Sen Yin; Wanlong Tan; Dong Xiao; Yunceng Weng; Wenjing Wang; Tingting Li; Junwen Shi; Lifang Shuai; Hongwei Li; Jianhua Zhou; Jean-Pierre Allain; Chengyao Li
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

10.  Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.

Authors:  Peirong Chen; Shoko Nogusa; Roshan J Thapa; Calvin Shaller; Heidi Simmons; Suraj Peri; Gregory P Adams; Siddharth Balachandran
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.